Lymphoma
Conditions
Keywords
Lymphoma, Prognosis, Biomarker, Quality of life
Brief summary
The purpose of this study is to establish a model which can predict the treatment outcome and the risk of treatment-related morbidity in patients with lymphoma.
Detailed description
Although the cure rate of lymphoma has been increased due to the development of newer effective drugs, a substantial portion of patients is still suffered from relapse. Furthermore, the treatment-related morbidity is another factor which can make the treatment outcome worse in patients with lymphoma, especially elderly patients. Thus, this study is going to assess factors which may affect the treatment outcome and the risk of treatment-related morbidity. 1.Biologic factors associated with the aggressiveness of lymphoma * molecular markers in serum, cytogenetic markers 2.Factors associated with the risk of treatment-related morbidity * comorbidity, nutrition status, performance status, quality of life at diagnosis
Interventions
None listed
Sponsors
Samsung Medical Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients who were diagnosed as lymphoma * Over 19 years old * Patients who agreed the enrollment of study * Informed consent for sampling
Exclusion criteria
•Patients who do not want to join the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| All cause mortality | 5 years | Disease and non-disease-related mortality including treatment-related death |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Treatment response | 1 year | Response to primary and salvage treatment Revised response criteria for lymphoma should be used (J Clin Oncol 2007;25(5):579-586). Complete response: disappearance of all evidence of disease Partial response: regression of measurable disease and no new sites Stable disease: failure to attain CR/PR or PD Relapsed disease or Progressive disease: Any new lesion or increase by \>=50% of previously involved sites from nadir |
| Rate of occurrence of toxicity | 2 years from the start of the 1st therapy | Infectious complications and other toxicities |
| Quality of life | 5 years | Change of quality of life |
| Biomarker development | 5 years | Biomarkers associated with treatment outcome |
Countries
South Korea
Outcome results
None listed